SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is seeing heightened trading activity and volatility as the community debates the implications of the FDA's second rejection of its melanoma drug, RP1. Investors are actively discussing the company's future following executive leadership changes at the FDA, with polarized opinions on whether management can force a regulatory reversal or if the company faces a long-term liquidity and survival challenge.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

Boost Run Inc. is trending as investors react to its recent Nasdaq debut and a significant partnership with Dell, which is fueling high-volume momentum. The community is actively debating the company's long-term potential as an NVIDIA Exemplar Cloud provider versus concerns regarding its post-SPAC volatility and lean corporate structure.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys is attracting significant attention as investors track its progress in establishing a domestic, China-free supply chain for critical heavy rare earth elements essential for U.S. defense systems ahead of upcoming procurement mandates. The community is actively debating the company's long-term execution capabilities and institutional backing, with discussions centered on its specialized metallization infrastructure and the strategic importance of replacing foreign-sourced materials.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trumps stock is trending amid intense online debate over his recent diplomatic trip to China and allegations of insider trading related to his financial disclosures. Investors and community members are actively clashing over the company's long-term viability, with vocal critics pointing to disappointing deal outcomes and retail shareholders navigating extreme volatility.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense volatility and retail-driven speculation centered on its role as a key supplier of indium phosphide substrates for AI-focused data center infrastructure. While proponents highlight a long-term supply bottleneck and structural industry demand, critics are heavily debating the sustainability of the stock's massive valuation relative to its current financials and active insider selling, leading to a polarized market environment.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token ($VVV) is attracting significant investor attention as a key player in the decentralized AI sector, with community sentiment fueled by active token burns, strategic model integrations, and speculation surrounding potential exchange listings. Despite short-term price volatility and community debate over accumulation patterns, long-term holders remain focused on the token's utility in providing private, uncensored AI access.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF (FXI) is seeing increased attention as investors closely monitor ongoing trade negotiations between the U.S. and China, with sentiment driven by conflicting signals regarding potential tariff reductions and geopolitical tensions. Market participants are actively tracking diplomatic developments and economic indicators, with many focusing on whether these trade discussions will lead to a durable policy reset or continue to cause volatility in Chinese large-cap equities.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently in the spotlight as investors analyze its role as a defensive retail stalwart amidst rising inflation and complex consumer spending data. The community is actively debating the stock's elevated valuation and recent insider activity against its reputation as a safe-haven asset, all while keeping a close watch on consumer health signals ahead of upcoming earnings.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is experiencing heightened market sensitivity and volatility as traders digest conflicting signals regarding US-China trade relations and upcoming high-level summits. While some investors are aggressively building long-term positions or rotating into China tech on valuation plays, others remain skeptical, citing continued regulatory uncertainty and persistent underperformance compared to domestic benchmarks.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining significant investor attention due to its strategic focus on domestic rare earth magnet production and supply chain independence. The community is actively discussing the stock's potential for a short-squeeze driven by its extremely low float, while weighing the company's tech integration against concerns over its post-merger volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer...

While SLS stock has surged nearly 300% over the past year, ATNM has climbed 7% over the same period. (Photo credit: Getty Images)

SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal?

Analyst estimates suggest ATNM carries the wider valuation runway, with 342% upside versus about 66% for SLS.

Equity

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting Actinium...

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting PR Newswire NEWYORK...

Are Medical Stocks Lagging  Actinium Pharmaceuticals (ATNM) This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

<ul class="summary-bullets"><li>The company’s latest research shows ATNM-400 achieving substantial tumor-growth suppression.</li><li>The therapy targets a validated antigen overexpressed in breast cancer and other solid tumors, such as Prostate Cancer and Non-Small Cell Lung Cancer.</li><li>Researchers observed that ATNM-400 induced irreversible DNA damage.</li></ul>Actinium Pharmaceuticals, Inc. (ATNM) stock was in the spotlight on Friday after the company announced promising new preclinical findings for its novel radiotherapy, ATNM-400, at the 2025 San Antonio Breast Cancer Symposium (SABCS).&nbsp;The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models, including hormone receptor–positive (HR+), triple-negative (TNBC), and treatment-resistant tumors.<h2 class="st-heading-2">ATNM-400’s Broad Potential</h2>The company’s latest research shows ATNM-400 achieving substantial tumor-growth suppression with minimal side effects in preclinical studies.&nbsp;The therapy targets a validated antigen overexpressed in breast cancer and other solid tumors, such as Prostate Cancer and Non-Small Cell Lung Cancer (NSCLC), positioning ATNM-400 as a potential pan-tumor radiotherapy solution.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ATNM">Actinium’s stock</a> traded over 3% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘neutral’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Effectiveness Against Resistant Cancer Types</h2>ATNM-400 displayed potent cytotoxic effects in models resistant to standard-of-care treatments, including trastuzumab-resistant BT474-Clone5 and tamoxifen-resistant MCF7-Tam1 cells. Combining ATNM-400 with conventional therapies like trastuzumab or tamoxifen enhanced tumor regression in preclinical models."Patients whose tumors progress after endocrine therapy or HER2-targeted therapies face limited and often toxic treatment options. The data presented at SABCS show that ATNM-400 generates potent, targeted DNA damage even in highly resistant breast cancer models, while maintaining a favorable tolerability profile,” said&nbsp;Aditya Bardia, Program Director, Breast Medical Oncology at Geffen School of Medicine, University of California, Los Angeles.Researchers observed that ATNM-400 induced irreversible DNA damage, marked by elevated phosphorylation of H2AX (pH2AX) and AKT (pAKT), consistent with alpha-particle–driven double-strand DNA breaks.&nbsp;ATNM stock has gained over 17% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-weighs-boosting-h200-ai-chip-production-report/cLICS1gREF8">Nvidia Weighs Boosting H200 AI Chip Production: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Actinium Pharmaceuticals, Inc. logo is displayed on the screen of a tablet. 

Why Is Actinium Pharmaceuticals Stock Rising Today? 

The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.

Are Medical Stocks Lagging  Alpha Cognition Inc. (ACOG) This Year?

Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. It also develops and markets medicines for relapsed and refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

Current Price	$1.25
Prev Close	$1.28
Open	$1.27
Dividend Yield	0.00%
50-Day Moving Average	$1.18
Beta	2.00
Avg. Volume	279,052.06
PE Ratio	-1.66

52-Week High	$1.95
52-Week Low	$0.9519
Market Capitalization	$39.22M
EPS (Annual)	-$1.09
Price to Book	17.02
Revenue Per Employee	$3,600.00

ATNM
Actinium Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ATNM News

ATNMActinium Pharmaceuticals Inc